GT Biopharma, Inc.
About GT Biopharma, Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2020
- $0
- Net income
- -$28.4M
- Total assets
- $8.1M
- Market cap
- $15.7M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Operating income
- -$12.4M
- Net income
- -$28.4M
- EPS (basic)
- $-6.68
- EPS (diluted)
- $-6.68
Balance sheet
- Total assets
- $8.1M
- Current assets
- $8.1M
- Total liabilities
- $2.3M
- Current liabilities
- $2.3M
- Shareholders’ equity
- $5.8M
Cash flow
- Operating cash flow
- -$12.9M
- Investing cash flow
- -$2.9M
- Financing cash flow
- $15.8M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $15.7M
- EPS (diluted)
- $-6.68
- Shares outstanding
- 37.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 11, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $28.4M in FY2020.
- Trading 89% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review GT Biopharma, Inc..
Write a review
News about GT Biopharma, Inc.
News & sentiment via Polygon.io
